Back

Effect of Aficamten on Cardiac Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Trial

1 September 2024 (08:15 - 08:26)
Organised by: Logo
Congress Presentation Part of: Trial updates and other studies in hypertrophic cardiomyopathy and aortic stenosis Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Ahmad Masri

Oregon Health & Science University Medical Group, Portland (United States of America)

7 More presentations in this session

Presentation thumbnail
Effect of Aficamten on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM
Doctor J. Spertus (Kansas City, US)
Slides Video
Presentation thumbnail
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Doctor S. Hegde (Dallas, US)
Slides Video
Presentation thumbnail
Safety and Outcomes of Standard of Care Medications Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in FOREST-HCM Trial
Doctor A. Masri (Portland, US)
Slides Video
Presentation thumbnail
Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis
Associate Professor M. Banovic (Belgrade, RS)
Slides Video
Presentation thumbnail
Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: A subanalysis from the DEDICATE-DZHK6 trial
Professor S. Bleiziffer (Bad Berka, DE)
Slides Video

Access the full session

Session thumbnail
Trial updates and other studies in hypertrophic cardiomyopathy and aortic stenosis
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
thumbnail
Congress Presentation
Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial
thumbnail
Congress Session
Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources